Type 2 diabetes mellitus (T2DM) is a complex endocrine and metabolic disorder, and a major public health problem that is rapidly increasing in prevalence. Although a wide range of pharmacotherapies for glycemic control is now available, management of T2DM remains complex and challenging. The kidneys contribute immensely to glucose homeostasis by reabsorbing glucose from the glomerular filtrate. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, a new class of antidiabetic agents that inhibit glucose absorption from the kidney independent of insulin, offer a unique opportunity to improve the outcomes of patients with T2DM. In this review, we provide an overview of two globally-approved SGLT2 inhibitors, dapagliflozin and canagliflozin, and discuss their effects and safety. This information will help clinicians to decide whether these drugs will benefit their patients.

Citations

Citations to this article as recorded by  

• Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study
  Jaehyuk Jang, Soyoon Park, Soohyun Kim, Sung-Hwan Kim, Yong-Seog Oh, Young Kyoung Sa, Youmi Hwang, Sung-Won Jang, Sang-Hyun Ihm, Young Choi
  European Journal of Preventive Cardiology.2024; 31(3): 320.     CrossRef
• Quantitative analysis of low-content impurity crystal forms in canagliflozin tablets by NIR solid-state analysis technique
  Mingdi Liu, Jichao Liu, Qiuhong Wang, Ping Song, Haichao Li, Zan Sun, Chenglong Shi, Weibing Dong
  Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2024; 311: 124000.     CrossRef
• A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin
  Pablo Lapuerta, Silvia Urbina, Jiaojuan He, Alyssa Wittle, Chenghai Li, Tong Li, Helen Wang, Marcus Hompesch
  Clinical Pharmacology & Therapeutics.2024;[Epub]     CrossRef
• Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial
  Kazuki Shiina, Hirofumi Tomiyama, Atsushi Tanaka, Takumi Imai, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Kaoru Dohi, Haruo Kamiya, Keisuke Kida, Toshihisa Anzai, Taishiro Chikamori, Koichi Node, Masayoshi Ajioka, Junya Ako, Rie Amano, Mit
  Hypertension Research.2023; 46(2): 495.     CrossRef
• Ecofriendly appraisal of stability‐indicating high‐performance chromatographic assay of canagliflozin and metformin with their toxic impurities; in silico toxicity prediction
  Raghda A. Emam, Aml A. Emam
  Journal of Separation Science.2023;[Epub]     CrossRef
• Effect of sodium‐glucose cotransporter 2 inhibitors on the rate of decline in kidney function: A systematic review and meta‐analysis
  Yanbei Duo, Junxiang Gao, Tao Yuan, Weigang Zhao
  Journal of Diabetes.2023; 15(1): 58.     CrossRef
• Quantitative analysis of low content polymorphic impurities in canagliflozin tablets by PXRD, NIR, ATR-FITR and Raman solid-state analysis techniques combined with stoichiometry
  Mingdi Liu, Jichao Liu, Qiuhong Wang, Ping Song, Haichao Li, Songgu Wu, Junbo Gong
  Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2023; 293: 122458.     CrossRef
• SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
  Bartosz Rolek, Mateusz Haber, Magdalena Gajewska, Sylwester Rogula, Arkadiusz Pietrasik, Aleksandra Gąsecka
  Journal of Cardiovascular Development and Disease.2023; 10(8): 322.     CrossRef
• Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes
  Somayeh Nazari, Hossein Mirkhani
  Current Diabetes Reviews.2023;[Epub]     CrossRef
• Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extensio
  Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon
  Diabetes & Metabolism Journal.2023; 47(6): 808.     CrossRef
• Novel perspective on cardiovascular adverse event profiles due to treatment with sodium-glucose transport protein 2 (SGLT2) inhibitors in the Japanese Adverse Drug Event Report (JADER) database
  Koji Suematsu
  Personalized Medicine Universe.2023; 12: 23.     CrossRef
• The fate of flavonoids after oral administration: a comprehensive overview of its bioavailability
  Abid Naeem, Yang Ming, Hu Pengyi, Kang Yong Jie, Liu Yali, Zhang Haiyan, Xiao Shuai, Li Wenjing, Wu Ling, Zhang Ming Xia, Liu Shan Shan, Zheng Qin
  Critical Reviews in Food Science and Nutrition.2022; 62(22): 6169.     CrossRef
• Add-on therapy with dapagliflozin in routine outpatient care of type 2 diabetes patients from Turkey: a retrospective cohort study on HbA1c, body weight, and blood pressure outcomes
  Derun Taner Ertugrul, Erdal Kan, Cigdem Bahadir Tura, Haci Bayram Tugtekin, Hayati Ayakta, Mehmet Celebioglu, Ceren Yılmaz, Onur Utebay, Ilhan Yetkin, Eren Gurkan, Kerem Sezer, Ramazan Gen, Suleyman Ozcaylak, Yildiz Okuturlar, Mehmet Coskun, Nilgun Govec
  International Journal of Diabetes in Developing Countries.2022; 42(1): 147.     CrossRef
• Sodium–glucose cotransporter 2 inhibitors do not increase the risk of fractures in real‐world clinical practice in Korea: A national observational cohort study
  Kyoung Hwa Ha, Dae Jung Kim, Yong Jun Choi
  Journal of Diabetes Investigation.2022; 13(6): 986.     CrossRef
• Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
  Yuki Yamauchi, Akinobu Nakamura, Takashi Yokota, Kiyohiko Takahashi, Shinichiro Kawata, Kazuhisa Tsuchida, Kazuno Omori, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Toshihisa Anzai, Shinya Tanaka, Yasuo Terauchi, Hideaki Miyoshi, Tatsuya Atsumi
  Scientific Reports.2022;[Epub]     CrossRef
• Blood glucose levels and bodyweight change after dapagliflozin administration
  Hyunah Kim, Seung‐Hwan Lee, Hyunyong Lee, Hyeon Woo Yim, Jae‐Hyoung Cho, Kun‐Ho Yoon, Hun‐Sung Kim
  Journal of Diabetes Investigation.2021; 12(9): 1594.     CrossRef
• Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation‐Induced Myocardial Dysfunction
  Yu‐Wen Lin, Chin‐Yu Chen, Jhih‐Yuan Shih, Bor‐Chih Cheng, Ching‐Ping Chang, Mao‐Tsun Lin, Chung‐Han Ho, Zhih‐Cherng Chen, Sudeshna Fisch, Wei‐Ting Chang
  Journal of the American Heart Association.2021;[Epub]     CrossRef
• Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
  Ja Young Jeon, Kyoung Hwa Ha, Dae Jung Kim
  Diabetes & Metabolism Journal.2021; 45(4): 505.     CrossRef
• Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
  Ji-Yeon Lee, Minyoung Lee, Ji Young Lee, Jaehyun Bae, Eugene Shin, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
  Diabetes & Metabolism Journal.2021; 45(6): 921.     CrossRef
• SGLT2i: beyond the glucose-lowering effect
  Lihua Ni, Cheng Yuan, Guopeng Chen, Changjiang Zhang, Xiaoyan Wu
  Cardiovascular Diabetology.2020;[Epub]     CrossRef
• Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
  Eugene Han, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
  Journal of Clinical Medicine.2020; 9(1): 259.     CrossRef
• Stability Indicating, pH and pKa Dependent HPLC–DAD Method for the Simultaneous Determination of Weakly Ionizable Empagliflozin, Dapagliflozin and Canagliflozin in Pharmaceutical Formulations
  Shahzad Sharif, Rashida Bashir, Ahmad Adnan, Sabiha Mansoor, Izaz Ahmad, Ayoub Rashid Ch, Muhammad Saqlain Tahir
  Chromatographia.2020; 83(12): 1453.     CrossRef
• Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials
  José Silva‐Cardoso, Omar Sheikh, Mouhamed Nashawi, Son Pham, Kelly M. Gallegos, Laith R. Dinkha, Robert J. Chilton
  Journal of Diabetes.2020; 12(4): 279.     CrossRef
• Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
  Jin Bong Choi, Je Mo Yoo, Ye-Jee Lee, Jae Woong Kim, Seung-Ju Lee, Hee Youn Kim, Dong Sup Lee, Seung-Hyun Ko, Hyun-Sop Choe
  International Neurourology Journal.2020; 24(1): 21.     CrossRef
• Sodium‐glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter‐organ crosstalk
  Jin Hee Kim, Minyoung Lee, Soo Hyun Kim, So Ra Kim, Byung‐Wan Lee, Eun Seok Kang, Bong‐Soo Cha, Jin Won Cho, Yong‐ho Lee
  Diabetes, Obesity and Metabolism.2019; 21(4): 801.     CrossRef
• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
  Scientific Reports.2019;[Epub]     CrossRef
• SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
  Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, Linxin Xu, Yunhong Lu, Ying Cheng, Ting Li, Xiaochen Yu, Bei Sun, Liming Chen
  Cardiovascular Diabetology.2019;[Epub]     CrossRef
• An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
  Ernest Adeghate, Sahar Mohsin, Faisal Adi, Fares Ahmed, Ali Yahya, Huba Kalász, Kornelia Tekes, Ernest A. Adeghate
  Expert Opinion on Investigational Drugs.2019; 28(9): 811.     CrossRef
• Stability‐indicating chromatographic and chemometric methods for environmentally benign determination of canagliflozin and its major degradation product; A comparative study and greenness assessment
  Aml A. Emam, Nada S. Abdelwahab
  Biomedical Chromatography.2019;[Epub]     CrossRef
• A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor
  You-Cheol Hwang, Jae Hyeon Kim, Byung-Wan Lee, Woo Je Lee
  Diabetes & Metabolism Journal.2019; 43(6): 898.     CrossRef
• Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
  Ji-Yeon Lee, Yongin Cho, Minyoung Lee, You Jin Kim, Yong-ho Lee, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang
  Diabetes & Metabolism Journal.2019; 43(2): 158.     CrossRef
• Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes – Results from a Retrospective Single-centre Study
  Manash P Baruah, Sanjay Kalra
  European Endocrinology.2019; 15(2): 113.     CrossRef
• Canagliflozin stability study and ecofriendly chromatographic determination of its degradation product: A comparative study
  Aml A. Emam
  Journal of Separation Science.2018; 41(4): 822.     CrossRef
• Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial
  Nam Hoon Kim, Soo Lim, Soo Heon Kwak, Min Kyong Moon, Jun Sung Moon, Yong-ho Lee, Ho Chan Cho, Juneyoung Lee, Sin Gon Kim
  BMJ Open.2018; 8(9): e022448.     CrossRef
• Short-term outcomes of patients with Type 2 diabetes mellitus treated with canagliflozin compared with sitagliptin in a real-world setting
  YL Shao, KH Yee, SK, Koh, YF Wong, LY Yeoh, S Low, CF Sum
  Singapore Medical Journal.2018; 59(5): 251.     CrossRef
• Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
  Soo Lim, Robert H. Eckel, Kwang Kon Koh
  Atherosclerosis.2018; 272: 33.     CrossRef
• Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
  Kyung Ae Lee, Heung Yong Jin, Na Young Lee, Yu Ji Kim, Tae Sun Park
  Diabetes & Metabolism Journal.2018; 42(4): 338.     CrossRef
• The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes
  Yanli Shao, Gwyneth Joy Lim, Chin Lian Chua, Yip Fong Wong, Ester Chai Kheng Yeoh, Serena Kiat Mun Low, Chee Fang Sum
  Diabetes Research and Clinical Practice.2018; 142: 85.     CrossRef
• Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease
  Dug-Hyun Choi, Chan-Hee Jung, Ji-Oh Mok, Chul-Hee Kim, Sung-Koo Kang, Bo-Yeon Kim
  Endocrinology and Metabolism.2018; 33(3): 387.     CrossRef
• Comparison between sodium–glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta‐analysis
  Yun Kyung Cho, Ye‐Jee Kim, Yu Mi Kang, Seung Eun Lee, Joong‐Yeol Park, Woo Je Lee, Chang Hee Jung
  Journal of Diabetes Investigation.2018; 9(4): 882.     CrossRef
• Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
  Eugene Han, Ari Kim, Sung Jae Lee, Je-Yon Kim, Jae Hyeon Kim, Woo Je Lee, Byung-Wan Lee
  Diabetes Therapy.2018; 9(4): 1689.     CrossRef
• Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
  Eugene Han, Eugene Shin, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha
  Frontiers in Endocrinology.2018;[Epub]     CrossRef
• Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes
  J.-Y. Lee, G. Kim, S.R. Kim, Y.-H. Lee, B.-W. Lee, B.-S. Cha, E.S. Kang
  Diabetes & Metabolism.2017; 43(2): 191.     CrossRef
• Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds
  Daniella B.R. Insuela, Vinicius F. Carvalho
  European Journal of Pharmacology.2017; 812: 64.     CrossRef
• Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J‐STEP/INS): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial
  Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku
  Diabetes, Obesity and Metabolism.2017; 19(10): 1397.     CrossRef
• A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
  Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Tae-Seok Lim, Ki-Ho Song, Ki-Dong Yoo, Yu-Bae Ahn, Seung-Hyun Ko
  Lipids in Health and Disease.2017;[Epub]     CrossRef
• Morning Spot Urine Glucose-to-Creatinine Ratios Predict Overnight Urinary Glucose Excretion in Patients With Type 2 Diabetes
  So Ra Kim, Yong-ho Lee, Sang-Guk Lee, Sun Hee Lee, Eun Seok Kang, Bong-Soo Cha, Hyun Chul Lee, Jeong-Ho Kim, Byung-Wan Lee
  Annals of Laboratory Medicine.2017; 37(1): 9.     CrossRef
• The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study
  So Ra Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Diabetes Therapy.2017; 8(3): 601.     CrossRef
• Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal Glycosuria
  Siqian Gong, Jiandong Guo, Xueyao Han, Meng Li, Lingli Zhou, Xiaoling Cai, Yu Zhu, Yingying Luo, Simin Zhang, Xianghai Zhou, Yumin Ma, Linong Ji
  The Journal of Clinical Endocrinology & Metabolism.2017; 102(5): 1548.     CrossRef
• Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
  Seok Joon Shin, Sungjin Chung, Soo Jung Kim, Eun-Mi Lee, Young-Hye Yoo, Ji-Won Kim, Yu-Bae Ahn, Eun-Sook Kim, Sung-Dae Moon, Myung-Jun Kim, Seung-Hyun Ko, Kwang-Hyun Baek
  PLOS ONE.2016; 11(11): e0165703.     CrossRef
• Sodium–glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes
  Stanley S. Schwartz, Intekhab Ahmed
  Current Medical Research and Opinion.2016; 32(5): 907.     CrossRef
• Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes
  Fida Bacha, Sara Klinepeter Bartz
  Pediatric Diabetes.2016; 17(8): 545.     CrossRef
• Renal threshold for glucose reabsorption predicts diabetes improvement by sodium‐glucose cotransporter 2 inhibitor therapy
  Aya Osaki, Shuichi Okada, Tsugumichi Saito, Eijiro Yamada, Kumeo Ono, Yawara Niijima, Hiroto Hoshi, Masanobu Yamada
  Journal of Diabetes Investigation.2016; 7(5): 751.     CrossRef
• Sodium-glucose co-transporter inhibition in the treatment of diabetes: Sweetening the pot
  Carlos A Alvarez, Ian J Neeland, Darren K McGuire
  Diabetes and Vascular Disease Research.2015; 12(2): 74.     CrossRef
• A simple and sensitive high performance liquid chromatography assay with a fluorescence detector for determination of canagliflozin in human plasma
  Muzaffar Iqbal, Nasr Y. Khalil, Amer M. Alanazi, Khalid A. Al-Rashood
  Analytical Methods.2015; 7(7): 3028.     CrossRef
• Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years
  Xiang-Yang Liu, Ning Zhang, Rui Chen, Jia-Guo Zhao, Pei Yu
  Journal of Diabetes and its Complications.2015; 29(8): 1295.     CrossRef
• Severe hypercalcemia and hypernatremia in a patient treated with canagliflozin
  Arshpreet Kaur, Stephen J Winters
  Endocrinology, Diabetes & Metabolism Case Reports.2015;[Epub]     CrossRef
• Pharmacological treatment and therapeutic perspectives of metabolic syndrome
  Soo Lim, Robert H. Eckel
  Reviews in Endocrine and Metabolic Disorders.2014; 15(4): 329.     CrossRef